Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Jounce

Bristol-Myers Squibb (BMS) building

BMS’ Opdivo/Yervoy combination demonstrates OS benefit

Better kidney cancer symptom control reported versus sunitinib was also reported

Celgene building

Celgene gains French reimbursement for Revlimid in multiple myeloma

HAS decides it offers ' significant improvement' over existing treatments

Bristol-Myers Squibb (BMS) building

BMS’ Opdivo defies naysayers with healthy growth

Third quarter sales of the PD1 inhibitor saw a 38% rise

- PMLiVE

BMS appoints Saurabh Saha as senior VP, global head of translational medicine

He joins the R&D team from Atlas Venture

- PMLiVE

Pfizer could raise ‘up to $15bn’ from consumer unit sale

Would follow in the footsteps of Novartis, Boehringer and Merck & Co if it does strike a deal

Bristol-Myers Squibb (BMS) building

NICE says OK to Opdivo for lung cancer via CDF

Comes after BMS drops the price of its PD-1 inhibitor

Bristol-Myers Squibb (BMS) building

BMS data add to checkpoint inhibitor combo confusion

Opdivo and Yervoy meet one objective but miss another in CheckMate-214

Celgene building

Celgene steps back from $1bn Sutro acquisition

Instead opts for amended licensing deal with US biotech

Bristol-Myers Squibb (BMS) building

BMS boosts immuno-oncology with $2.3bn IFM buy

Boston-based group will operate as a subsidiary of BMS

Celgene building

Celgene, Agios get FDA OK for leukaemia drug Idhifa

Duo’s drug becomes first new AML therapy since Novartis' Rydapt

- PMLiVE

BMS and Clovis join forces in PARP combo race

Duo will combine Opdivo and Rubraca in phase II and III trials to treat a variety of tumours

- PMLiVE

BMS and Clovis join forces in PARP combo race

Duo will combine Opdivo and Rubraca in phase II and III trials to treat a variety of tumours

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links